Saturday 17 October 2026
Export VRDN’s income statement to Excel — free account
Viridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024. In the quarter to June 2026, revenue grew 278.7%, EPS fell 5.00%, free cash flow fell 41.4% and total debt rose 1,064.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
19.03
0.53
−2.71%
Follow VRDN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (86.93%) | (78.43%) | (63.87%) | (72.53%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
4 | 2 | 3 | 3 | |
| (46.08%) | (49.74%) | (41.73%) | (44.77%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (622.21%) | |
Return on Tangible Assets |
(37.93%) | (49.12%) | (41.54%) | (57.81%) | |
Average Days of Receivables |
384.87 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.11) | (2.97) | (3.26) | (3.99) | |
Free Cash Flow |
(335.04) | (303.82) | (276.89) | (326.34) | |
Capital Expenditures |
(1.70) | (0.43) | (0.49) | (0.37) | |
| Other line items | |||||
Cash ROIC |
(17.77%) | (20.97%) | (16.81%) | (32.16%) | |
Accounts Receivable Turnover |
1.89 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
456.47% | 479.04% | 478.38% | 454.42% | |
Selling, General and Administrative Expense of Revenue |
213.21% | 164.83% | 134.53% | 109.09% | |
Share Based Compensation of Revenue |
75.38% | 66.94% | 62.53% | 58.33% | |
Interest Coverage |
(25.89) | (49.07) | (73.44) | (155.65) | |
Operating CF/Net income |
0.86 | 0.84 | 0.81 | 1.08 | |
Depreciation/Fixed assets |
(2.07) | (5.16) | (5.13) | (6.89) | |
Capex/Depreciation |
0.30 | 0.07 | 0.08 | 0.05 | |
Revenue per Share |
0.66 | 0.69 | 0.84 | 0.87 | |
Operating CF per Share |
(3.09) | (2.97) | (3.26) | (3.99) | |
Capex per Share |
(0.02) | 0.00 | (0.01) | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.01 |
Columns are period end dates